ArchiveAugust 2021

Survey on the impact of the COVID-19 pandemic on people’s health and quality of life

Has the COVID-19 pandemic affected your health and quality of life? If so, please consider taking part in this survey that we are involved in. Professor Carol Rivas at UCL is currently leading an 18-month UK study on the impact of the COVID-19 pandemic on people’s health and quality of life. The Coronavirus Chronic Conditions and Disabilities Awareness Study (CICADA, ) is funded by the...

Is MS the new paraneoplastic disorder?

The most interesting of scientific discoveries are sometimes hidden in the most obscure of places. In this case an open access journal that I’d never heard of before, and a discussion from the authors that is close but no cigar. The authors report of a 39-year-old woman who presented with a demyelinating brain lesion, but on further search was found to also have a thymoma (a thyroid cancer)...

Severed

Cast your mind back… Can you remember the very first time when your body began acting independently? Was it an unexpected stumble, a bout of double vision that mysteriously came and went or a spell of numbness? And your reaction? Confusion, disbelief or even fear? Pre-illness, we take our bodies for granted. As healthy adults we move through the day, confident our body will simply “follow” our...

C-sections: how common are they in women with MS?

Barts-MS rose-tinted-odometer: ★★ (Indian summer orange #FF7722) I have always said that women with early MS who start and extend families should have no reason to worry about additional problems with their pregnancy and childbirth because. It may be different for women with more advanced MS who are disabled. Maybe I should revise this general advice based on the study below.In this study, 15...

Ok so now we know T cells after CD20 but blunted antibody response again

It is clear people with MS make a T cell response even on anti CD20. Many make an anti spike antibody response but tend to make less neutralising response against the receptor binding domain of spike.. What does it mean?….I think it means you are at a greater risk of symptomatic covid 19 if you are on anti CD 20 and don’t make an antibody response. I think even in those that do…...

MSCOVID-19 Importance of antibody production to prevent infection.

Although we have made the case that antibodies may not be essential to deal with the virus, it is clear that antibodies are centrally important in limiting infection. This can be seen in this Russian study. If you made antibodies after infection you did OK and much better than if you only made T cell responses Ivan Molodtso et al .A prospective study of the protective effect of SARS-CoV-2...

Brutons Tyrosine Kinase Inhibitors for Relapsing MS

The race is on between the different Pharma to get their Brutons tyrosine kinase inhibitors into the clinic. There are at least four different variants in the hunt and most are been tested in phase III studies in relapsing and progressive MS. They inhibit B cell activation so perhaps unsurprisingly they inhibit relapsing MS and this can be shown within a few weeks using MRI outcomes, as shown...

MSCOVID19 more of the Same Old, Same Old

So it is becoming more and more clear that some form of T cell response is made after COVID-19 infection even if you dont make a B cell repsonse if you have been treated with anti-CD20 and this is reflected in what we see after vaccination. What are we going to do with this information….it seems like the answer is nothing…at the moment. Iannetta M, Landi D, Cola G, Malagnino V, Teti...

Back to school: Does one new MRI lesion matter?

Although neurologists love to brag about their ‘fingerspitzengefühl’, pwMS will have experienced that the clinical examination is only a smokescreen for what really determines clinical management: brain imaging. Especially during the COVID-19 pandemic, MRI was our germ-free way into an MS brain. The goal of requesting an MRI is to compare the number and volume of MS lesions with the previous scan...

Anti-HERV antibody trial-Failure

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F.Mult Scler. 2021 : 13524585211024997...

Translate

Categories

Recent Posts

Recent Comments

Archives